AUTHOR=Xie Xiao-Hong , Deng Hai-Yi , Lin Xin-Qing , Wu Jian-Hui , Liu Ming , Xie Zhan-Hong , Qin Yin-Yin , Zhou Cheng-Zhi 

TITLE=Case Report: Nintedanib for Pembrolizumab-Related Pneumonitis in a Patient With Non-Small Cell Lung Cancer

JOURNAL=Frontiers in Oncology

VOLUME=11

YEAR=2021

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.673877

DOI=10.3389/fonc.2021.673877

ISSN=2234-943X

ABSTRACT=<p>Pembrolizumab, an immune checkpoint inhibitor (ICI) approved for advanced non-small cell lung cancer (NSCLC) treatment, has shown superior survival benefits. However, pembrolizumab may lead to severe immune-related adverse events (irAEs), such as checkpoint inhibitor-related pneumonitis (CIP). The routine treatment of CIP was based on systemic corticosteroids, but the therapies are limited for patients who are unsuitable for steroid therapy. Here, we present the first successful treatment of nintedanib for pembrolizumab-related pneumonitis in a patient with advanced NSCLC.</p>